Details of the SBP | SYNBIP

General Information of Synthetic Binding Protein (SBP) (ID: SBP001677)
SBP Name	scFv anti-CD22 BL22
Synonyms	scFv BL22
Design Method	Traditional methods (Site-directed mutagenesis and/or Directed evolution)
Expression System	Mammalian cells
Selection Method	HEK 293T cell surface display
Highest Status	Research

Protein Scaffold Information of This SBP
Scaffold ID	PS057 Scaffold Info					[1]
Scaffold Name	scFv
Scaffold Class	Antibody fragment
Fold Type	Beta-Sheets + Loops

Binding Target(s) of This SBP (BTS)

BTS Name	Details	Mechanism	Application	Affinity	Research Organization	Ref
B-cell receptor CD22	BTS Info	Binder	CD22-expressing cancers	Kd: 5.8 nM	National Cancer Institute	[1]

Clinical Trial Information of This SBP
NCT00021983	Click to show the Detail
Indication	Leukemias; Lymphomas
Phase	Phase I
Title	Phase I Study of BL22, a Recombinant Immunotoxin for Treatment of CD22+ Leukemias and Lymphomas
Status	Completed
Sponsor	National Cancer Institute (NCI)
NCT00024115	Click to show the Detail
Indication	CD22-Positive B-Cell Non-Hodgkin's Lymphoma; Chronic Lymphocytic Leukemia
Phase	Phase I
Title	Phase I Study of Recombinant?BL22?Immunotoxin in Patients With CD22-Positive B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
Status	Withdrawn
Sponsor	National Cancer Institute (NCI)
NCT00924040	Click to show the Detail
Indication	Hairy Cell Leukemia
Phase	Phase II
Title	Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia
Status	terminated
Sponsor	National Cancer Institute (NCI)

References

1

Isolation of anti-CD22 Fv with high affinity by Fv display on human cells. Proc Natl Acad Sci U S A. 2006 Jun 20;103(25):9637-42.